IgG N-糖基化与2型糖尿病神经病变及肾病发病关系的前瞻性队列汇总分析
该研究汇总分析了EPIC-Potsdam、DiaGene、GenoDiabMar和Hoorn DCS四个前瞻性队列,共纳入3,263名在糖基化检测时有或无2型糖尿病的个体,随访至糖尿病诊断后发生674例神经病变和639例肾病。采用Cox模型分析IgG N-糖基化峰与结局的关联并跨队列荟萃分析。结果显示,无半乳糖、无唾液酸和双分支IgG-GPs与肾病风险升高相关,而半乳糖化和唾液酸化IgG-GPs与风险降低相关;IgG-GPs与神经病变的关联经多重检验校正后无统计学意义。
要点
- 无半乳糖/无唾液酸/双分支IgG-GPs与糖尿病肾病风险升高相关。
- 半乳糖化和唾液酸化IgG-GPs与糖尿病肾病风险降低相关。
- IgG-GPs与糖尿病神经病变的关联经多重检验校正后无统计学意义。
核心结论
- IgG N-糖基化可能反映与糖尿病肾病相关的免疫机制。
- IgG-GPs与糖尿病神经病变的证据仍不确定。
研究设计与样本
- 汇总分析四个前瞻性队列:EPIC-Potsdam、DiaGene、GenoDiabMar和Hoorn DCS。
- 共纳入3,263名在糖基化检测时有或无2型糖尿病的个体。
- 随访至糖尿病诊断后发生674例神经病变和639例肾病。
- 使用Cox模型分析IgG-GPs及性状与发病结局的关联,并跨队列荟萃分析。
主要发现
- IgG-GP3与肾病风险升高相关(HR 1.13,95%CI 1.04-1.24)。
- IgG-GP4与肾病风险升高相关(HR 1.15,95%CI 1.05-1.26)。
- IgG-GP14与肾病风险降低相关(HR 0.86,95%CI 0.78-0.94)。
- IgG-GP18与肾病风险降低相关(HR 0.85,95%CI 0.77-0.94)。
- 上述肾病关联均FDR<0.05;IgG-GPs与神经病变的关联经多重检验校正后无统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether IgG N-glycosylation patterns are prospectively associated with incident diabetic nephropathy and neuropathy. RESEARCH DESIGN AND METHODS: We analyzed IgG N-glycosylation profiles in four cohorts: EPIC-Potsdam, DiaGene, GenoDiabMar, and Hoorn DCS. Among 3,263 individuals with and without type 2 diabetes at profiling, 674 incident neuropathy and 639 incident nephropathy cases occurred after diabetes diagnosis. Associations of IgG N-glycan peaks (IgG-GPs) and traits with incident outcomes were examined using Cox models and meta-analyzed across cohorts. RESULTS: Agalactosylated, asialylated, and bisected IgG-GPs were associated with higher nephropathy risk (IgG-GP3: hazard ratio [HR] 1.13 [95% CI 1.04-1.24]; IgG-GP4: HR 1.15 [95% CI 1.05-1.26]), while galactosylated and sialylated IgG-GPs were associated with lower risk (IgG-GP14: HR 0.86 [95% CI 0.78-0.94]; IgG-GP18: HR 0.85 [95% CI 0.77-0.94]) (all false discovery rate <0.05). Associations of IgG-GPs with incident neuropathy were rendered nonsignificant after multiple testing correction. CONCLUSIONS: IgG N-glycosylation may reflect immune-related mechanisms relevant to diabetic nephropathy; but the evidence between IgG-GPs and diabetic neuropathy remains inconclusive.
引用
- Martinez Escobedo C, Birukov A, Heijmans R, et al. IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies. Diabetes Care. 2026. PMID: 42467059. doi:10.2337/dc26-0620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。